Can a diabetes drug protect kidneys in heart failure patients?
NCT ID NCT06030843
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether empagliflozin, a diabetes drug, can prevent death, new dialysis, or lasting kidney damage in people with cardiorenal syndrome type 1—a condition where heart failure suddenly worsens kidney function. About 200 hospitalized adults will receive either empagliflozin or a placebo for 30 days. The goal is to see if the drug helps preserve kidney function and improve survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Empagliflozin 10 mg
- What this could lead to
- If it works, this could point toward a treatment that protects kidneys and reduces the need for dialysis in patients with heart and kidney failure.
- What could go wrong
- This is a mid-stage trial with 200 participants, so results may not apply to everyone. The drug may not improve outcomes and could cause side effects like dehydration or low blood pressure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EMPAGLIFLOZIN IN CARDIORENAL SYNDROME TYPE 1 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Faculty of Medicine, Chulalongkorn University
RECRUITINGBangkok, Pathumwan, 10330, Thailand